In this HCPLive RX Review Special Report, Albert Rizzo, MD, and James Chalmers, MBChB, PhD, turn their attention to brensocatib, the first FDA-approved therapy for non–cystic fibrosis bronchiectasis as of August 2025, marketed as Brinsupri. Brensocatib, a selective and reversible inhibitor of dipeptidyl peptidase 1, targets neutrophil-driven inflammation, an underlying driver of disease progression. Chalmers reviews findings from the phase 3 ASPEN trial, which enrolled over 1,700 patients and demonstrated a 20% reduction in exacerbations across both tested doses, with the higher dose also slowing lung function decline and showing nominal improvements in symptoms.
